Last updated on June 2020

Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity


Brief description of study

The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight, hunger assessments and other factors in patients with rare genetic disorders of obesity, including POMC deficiency, LepR deficiency, Bardet-Biedl syndrome and Alstrm syndrome.

Clinical Study Identifier: NCT03013543

Find a site near you

Start Over

Marshfield Clinic

Birmingham, United Kingdom
  Connect »

Honor Health Research Institute

Scottsdale, AZ United States
  Connect »

Axis Clinical Trials-Downtown

Los Angeles, CA United States
  Connect »

Axis Clinical Trials Headquarters

Los Angeles, CA United States
  Connect »

San Diego Wake Research

San Diego, CA United States
  Connect »

Florida Hospital

Orlando, FL United States
  Connect »

Maine Medical Partners

Portland, ME United States
  Connect »

Baystate Medical Center

Springfield, MA United States
  Connect »

Washington University St. Louis

Saint Louis, MO United States
  Connect »

Impact Clinical Trials

Las Vegas, NV United States
  Connect »

University of Buffalo

Buffalo, NY United States
  Connect »

AXIS Clinical Trials

New York, NY United States
  Connect »

Wake Research Inc.

Raleigh, NC United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

University of Utah

Salt Lake City, UT United States
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

Hammersmith Hospital

London, United Kingdom
  Connect »

Columbia University

New York, NY United States
  Connect »

Wake Research TN

Chattanooga, TN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.